首页 | 本学科首页   官方微博 | 高级检索  
     

116例携带乙肝病毒的淋巴瘤患者化疗后发生肝功能损害的临床分析
引用本文:Li YH,He YF,Wang FH,Lin XB,Xia ZJ,Sun XF,Lin TY,Huang HQ,Zhang L,Xu RH,Jiang WQ,Guan ZZ. 116例携带乙肝病毒的淋巴瘤患者化疗后发生肝功能损害的临床分析[J]. 癌症, 2005, 24(12): 1507-1509
作者姓名:Li YH  He YF  Wang FH  Lin XB  Xia ZJ  Sun XF  Lin TY  Huang HQ  Zhang L  Xu RH  Jiang WQ  Guan ZZ
作者单位:华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心内科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心内科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心内科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心内科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心内科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心内科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心内科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心内科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心内科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心内科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心内科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心内科,广东,广州,510060
摘    要:背景与目的:有研究显示,携带慢性乙型肝炎病毒(hepatitisBvirus,HBV)的恶性肿瘤患者化疗后肝功能损害发生率及相关死亡率明显增加。本研究探讨携带慢性HBV的淋巴瘤患者接受化疗后,肝功能损害的发生情况及其临床后果,并进一步探讨临床相关的高危因素。方法:1985年1月至2002年1月在我院门诊及住院的携带HBV的116例淋巴瘤患者,回顾性分析其接受化疗后肝功能损害的发生情况、临床后果及其相关高危因素。结果:60例(51.7%)患者化疗后出现肝功能损害,按WHO肝脏毒性标准,Ⅰ度4例(3.4%)、Ⅱ度14例(12.1%)、Ⅲ度15例(12.9%)、Ⅳ度27例(23.3%)。经对症治疗后11例(9.5%)患者按期化疗,27例(23.3%)化疗延期,16例(13.8%)终止化疗,6例(5.2%)死亡。应用二值多元logistic回归模型,应用激素是化疗后发生肝炎的高危因素。结论:携带HBV的淋巴瘤患者化疗后肝功能损害发生率高,化疗后肝功能损害会导致患者化疗延迟,甚至死亡。应用激素是其发生的高危因素。

关 键 词:淋巴瘤/化学疗法  乙肝病毒携带/并发症  肝功能损害
文章编号:1000-467X(2005)12-1507-03
收稿时间:2005-01-05
修稿时间:2005-02-25

Clinical analysis of liver damage of 116 malignant lymphoma patients with chronic HBV infection after cytotoxic chemotherapy
Li Yu-Hong,He Yi-Fu,Wang Feng-Hua,Lin Xu-Bin,Xia Zhong-Jun,Sun Xiao-Fei,Lin Tong-Yu,Huang Hui-Qiang,Zhang Li,Xu Rui-Hua,Jiang Wen-Qi,Guan Zhong-Zhen. Clinical analysis of liver damage of 116 malignant lymphoma patients with chronic HBV infection after cytotoxic chemotherapy[J]. Chinese journal of cancer, 2005, 24(12): 1507-1509
Authors:Li Yu-Hong  He Yi-Fu  Wang Feng-Hua  Lin Xu-Bin  Xia Zhong-Jun  Sun Xiao-Fei  Lin Tong-Yu  Huang Hui-Qiang  Zhang Li  Xu Rui-Hua  Jiang Wen-Qi  Guan Zhong-Zhen
Affiliation:1. State Key Laboratory of Oncology in Southern China, Guangzhou, Guangdong, 510060, P. R. China; 2. Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, P. R. China
Abstract:BACKGROUND & OBJECTIVE: Chronic hepatitis B virus (HBV) infection increases the prevalence of liver damage and related death of malignant tumor patients. This study was to investigate the prevalence of liver damage and clinical results in lymphoma patients with chronic HBV infection after standard chemotherapy, and assess high risk factors associated with liver damage for better guidance in clinic. METHODS: Records of 116 lymphoma patients with chronic HBV infection, treated with standard chemotherapy from Jan. 1985 to Jan. 2002 in Cancer Center of Sun Yat-sen University, were reviewed to analyze the prevalence of liver damage, clinical results, and related high risk factors. RESULTS: Of the 116 patients, 60 (51.7%) suffered liver damage. According to WHO criteria of liver toxicity, 4 (3.4%) were in grade I, 14 (12.1%) in grade II, 15 (12.9%) in grade III, and 27 (23.3%) in grade IV. After treatment for liver damage, 11 (9.5%) patients completed chemotherapy without delay, 27(23.3%) completed chemotherapy with delay of more than 8 days, 16(13.8%) terminated chemotherapy, 6(5.2%) died. Logistic multivariate analysis showed that steroid was a high risk factor of liver damage after chemotherapy. CONCLUSIONS: The prevalence of liver damage is high in lymphoma patients with chronic HBV infection after standard chemotherapy, which led to treatment delay or discontinue, even death. Steroid is a high risk of liver damage.
Keywords:Lymphoma/chemotherapy  Hepatitis B virus carrier/complication  Liver damage
本文献已被 CNKI 维普 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号